2-47410167-T-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_000251.3(MSH2):āc.440T>Gā(p.Val147Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000682 in 1,614,012 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152154Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251436Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135888
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461858Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727230
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152154Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 74340
ClinVar
Submissions by phenotype
not provided Uncertain:3
This variant is denoted MSH2 c.440T>G at the cDNA level, p.Val147Gly (V147G) at the protein level, and results in the change of a Valine to a Glycine (GTT>GGT). This variant was observed in a cohort of breast cancer patients, unselected for family history (Tung 2016). MSH2 Val147Gly was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located in the connector domain (L?tzen 2008, Kansikas 2011). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether MSH2 Val147Gly is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
The MSH2 c.440T>G; p.Val147Gly variant (rs760851623) is reported in the literature in one individual affected with breast cancer (Tung 2016). This variant is also reported in ClinVar (Variation ID: 420893). This variant is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. A massively parallel cell based functional assay with susceptibility to DNA damaging agent, 6-thioguanine (6-TG), suggests the functionality of this variant to be neutral (Jia 2021). However, computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.645). Due to limited information, the clinical significance of this variant is uncertain at this time. References: Jia X et al. Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk. Am J Hum Genet. 2021 Jan 7;108(1):163-175. PMID: 33357406. Tung N et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016 May 1;34(13):1460-8. PMID: 26976419. -
Variant summary: The c.440T>G (p.Val147Gly) in MSH2 gene is a missense change that involves a non-conserved nucleotide and 3/5 in silico tools predict deleterious outcome. The variant of interest is located outside of any known functional domain or repeats, however no studies determining the functional impact of this variant have been conducted and published at the time of evaluation. The variant is present in the large control population dataset of ExAC at a frequency 0.000016 (2/121412 chrs tested), which does not exceed the maximal expected frequency of a pathogenic allele (0.00057) in this gene. The variant is variant has been reported in 1 BrC patient without strong evidence for causality. The c.440T>G has not been cited by a reputable database/clinical laboratory. Taking together, the variant was classified as VUS. -
Hereditary cancer-predisposing syndrome Uncertain:2
The p.V147G variant (also known as c.440T>G), located in coding exon 3 of the MSH2 gene, results from a T to G substitution at nucleotide position 440. The valine at codon 147 is replaced by glycine, an amino acid with dissimilar properties. This alteration was seen in 1/732 breast cancer patients, 1/189 colorectal cancer patients and 0/490 cancer-free elderly controls in a Turkish population (Akcay IM et al. Int J Cancer, 2021 Jan;148:285-295). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was determined to be functionally neutral (Jia X et al. Am J Hum Genet, 2021 Jan;108:163-175). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
This missense variant replaces valine with glycine at codon 147 of the MSH2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373).This variant does not impact MSH2 function in a 6-thioguanine sensitivity assay in haploid human cells (internally defined LOF score threshold <= -1.32, PMID: 33357406). This variant has been reported in an individual affected with breast cancer (PMID: 26976419). This variant has been identified in 2/251436 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
MSH2-related disorder Uncertain:1
The MSH2 c.440T>G variant is predicted to result in the amino acid substitution p.Val147Gly. This variant was reported as a variant of uncertain significance in a cohort of individuals with breast cancer (Table A2 in Tung et al 2016. PubMed ID: 26976419). This variant is reported in 0.0029% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-47637306-T-G) and is reported in ClinVar as likely benign and uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/420893/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Lynch syndrome Uncertain:1
This missense variant replaces valine with glycine at codon 147 of the MSH2 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 26976419). This variant has been identified in 2/251436 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at